Abstract 2930: Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systems
Panot Sainamthip(Dana-Farber Cancer Institute), Harshabad Singh(Brigham and Women's Hospital), Julien Dilly(Massachusetts Institute of Technology), Seema Chugh(Broad Institute), Andrew J. Aguirre(Broad Institute), Jiajia Chen(Dana-Farber Cancer Institute), Junning Wang(Dana-Farber Cancer Institute), Kazuki Takahashi(University of Occupational and Environmental Health Japan), David Tak Wai Lui(Chinese University of Hong Kong)
Cited by 1
Related Papers
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
|Cancer Discovery|2016|632
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
|Cell|2021|586